UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak

By: via Benzinga
In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on Ariad Pharmaceuticals (NASDAQ: ARIA) from ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.